泓博醫(yī)藥(股票代碼：301230)成立于2007年，總部位于上海，致力于為全球醫(yī)藥客戶提供新藥研發(fā)和商業(yè)化生產(chǎn)一站式綜合服務(wù)，涵蓋藥物發(fā)現(xiàn)、制藥工藝的研究開(kāi)發(fā)以及原料藥、中間體的商業(yè)化生產(chǎn)等領(lǐng)域。目前，公司擁有超過(guò)22000平方米研發(fā)實(shí)驗(yàn)室(37000平方米臨床前新藥研發(fā)基地在建中）以及60000平方米生產(chǎn)基地，研發(fā)技術(shù)人員占比超63%。在16年的征途中,泓博醫(yī)藥通過(guò)特有的“CRO”和“CDMO業(yè)務(wù)模式,構(gòu)建了全方位綜合性技術(shù)平臺(tái),為國(guó)內(nèi)外客戶的新藥研發(fā)提供了有力支撐。
PharmaResources（StockCode：301230.SZ）was founded in 2007 and is headquartered in Shanghai. The company is committed to providing comprehensive services for global pharmaceutical clients, including new drug research and development and commercial production, covering areas such as drug discovery, pharmaceutical process research and development, as well as commercial production of active pharmaceutical ingredients and intermediates. Currently, the company has over 22,000 square meters of R&D laboratories (with a 37,000 square meter preclinical new drug R&D base under construction) and a 60,000 square meter production base. R&D technical personnel account for over 63% of the workforce. Over the course of its 16-year journey, PharmaResources has established a comprehensive technical platform through its unique 'CRO' and 'CDMO' business models, providing strong support for the new drug development of domestic and international clients.